Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
March 04 2024 - 3:01PM
Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage
biotechnology company advancing differentiated biologics for the
treatment of atopic dermatitis, chronic obstructive pulmonary
disease, asthma and other inflammatory and immunology (I&I)
indications, today announced it will report interim results from
the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5,
2024. Following the announcement, the Company will host a
conference call and webcast at 7:00am ET to discuss the results.
To access the live and archived webcast, please visit the
Investor Relations page of Apogee’s website at
https://investors.apogeetherapeutics.com/news-events/events. The
archived webcast will be available for a limited time on the
Company’s website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company
seeking to develop differentiated biologics for the treatment of
atopic dermatitis (AD), chronic obstructive pulmonary disease
(COPD), asthma and other inflammatory and immunology indications
with high unmet need. Apogee’s antibody programs are designed to
overcome limitations of existing therapies by targeting
well-established mechanisms of action and incorporating advanced
antibody engineering to optimize half-life and other properties.
The company’s two most advanced programs are APG777 and APG808,
which are being initially developed for the treatment of AD and
COPD, respectively. Based on a broad pipeline and depth of
expertise, the company believes it can deliver value and meaningful
benefit to patients underserved by today’s standard of care.
Investor Contacts:
Noel KurdiVP, Investor RelationsApogee
TherapeuticsNoel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick1AB dan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Sep 2023 to Sep 2024